Paul Tudor Jones Crispr Therapeutics Ag Transaction History
Tudor Investment Corp Et Al
- $25.1 Billion
- Q4 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 18,337 shares of CRSP stock, worth $805,361. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,337
Previous 46,999
60.98%
Holding current value
$805,361
Previous $2.21 Million
67.35%
% of portfolio
0.0%
Previous 0.01%
Shares
19 transactions
Others Institutions Holding CRSP
# of Institutions
486Shares Held
64.1MCall Options Held
1.64MPut Options Held
1.93M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.97MShares$394 Million3.09% of portfolio
-
Capital International Investors Los Angeles, CA8.74MShares$384 Million0.07% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.81MShares$167 Million0.09% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$122 Million0.0% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.2.75MShares$121 Million0.07% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $3.43B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....